May 2020

Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nature Medicine, DZHK authors: A. Moretti, P. Hoppmann, A. B. Meier, T. Bozoglu, A. Baehr, C. M. Schneider, D. Sinnecker, K. Klett, F. Abdel Rahman, T. Haufe, S. Sun , V. Jurisch, R. Hinkel, R. Dirschinger, E. Martens, C. Jilek, G. Santamaria, B. Campbell, A. Wolf, T. Ziegler, S. Lee, T. Dorn, A. Dendorfer, K. L. Laugwitz, E. Wolf, and C. Kupatt

Duchenne muscular dystrophy (DMD) represents the most frequent hereditary childhood myopathy, leading to progressive muscle degeneration and weakness, and to premature death due to respiratory and cardiac failure. The X-chromosomal location of DMD renders 1 in 3,500 to 5,000 male newborns affected.

The vast majority of patients carry frameshift mutations in the DMD gene encoding dystrophin (DMD), which are mainly exon deletions. Recently, Crispr/Cas9-based gene editing strategies have demonstrated an efficient and permanent genomic correction in murine mdx models. Moreover, intravenous (i.v.) application of AAV9 delivering CRISPR/Cas9 components in a beagle model of DMD (exon 50 deficiency) proved successful in restoring expression of a shortened dystrophin in various muscles, including the heart. However, functional data have not been reported as of yet.

In a consortium of DZHK-scientists from Internal Medicine at TUM as well as LMU and Helmholtz-Munich, pigs of a transgenic strain lacking dystrophin exon 52 were investigated with regard to skeletal muscle function and electrophysiological stability of the heart. The researchers were able to demonstrate that a systemic infusion of AAV9-Crispr-Cas9 combined with appropriate guide RNAs sufficed to express a shortened, but stable dystrophin in many muscles, including the diaphragm and heart.

Moreover, high-resolution electrophysiological mapping in the diseased pigs, which died of sudden cardiac death no later than 105 days after birth, revealed a large area of vulnerable myocardium. This area was found reduced by the AAV9-Cas9-gRNA treatment, extending life span of the treatment group significantly. Consistently, human iPS-derived cardiomyocytes subjected to analogous AAV6-Cas9-gRNA transduction demonstrated dystrophin expression combined with a normalization of calcium handling. These findings demonstrate in preclinical large animal experiments,  that gene editing by Crispr-Cas9 in DMD is capable of inducing dystrophin expression, and improving heart and skeletal muscle functions.

Publication